Correspondingly, combined treatment with AKT- and EGFR-inhibitors synergistically inhibits the growth of preclinical models of EGFRM+ NSCLC resistant to erlotinib, gefitinib or osimertinib [291]. Here, AKT1 is linked to non-small cell lung carcinoma.